Positron Emission Tomography in Prostate Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- Washington University School of Medicine
- Enrollment
- 179
- Locations
- 1
- Primary Endpoint
- Determine the role of AC-PET in changing initial patient management
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
RATIONALE: Diagnostic procedures, such as positron emission tomography using carbon-11 acetate, may help find metastases from prostate cancer and may help predict whether prostate cancer will come back after treatment.
PURPOSE: This clinical trial is studying how well positron emission tomography using carbon-11 acetate works in finding metastases and predicting recurrence in patients with prostate cancer who are at risk for recurrence after treatment.
Detailed Description
The overall goal of this project is determination of the role of PET in patients with newly diagnosed medium- and high-risk prostate cancer in whom the standard clinical and imaging workup is negative. Thus, the incremental value of PET will be determined in this important group.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Determine the role of AC-PET in changing initial patient management
Time Frame: Completion of patient treatment
Secondary Outcomes
- Determine the value of AC-PET in predicting recurrence(Minimum of 2 years and maximum of 5 years)
- Assess the performance of AC-PET for detection of lymph node metastasis by comparison with biopsy.(Minimum of 2 years and maximum of 5 years)